Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 59 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA 2017;318:1700-1. [Ref.ID 102140]
2. Cita con resumen
Gao S-Y, Wu Q-J, Zhang T-N, Shen Z-Q, Liu C-X, Xu X, Ji C, Zhao Y-H. Fluoxetine and congenital malformations: a systematic review and meta-analysis of cohort studies. Br J Clin Pharmacol 2017;83:2134. [Ref.ID 102080]
3. Cita con resumen
Persson M, Cnattingius S, Villamor E, Söderling J, Pasternak B, Stephansson O, Neovius M. Risk of major congenital malformations in relation to maternal overweight and obesity severity: cohort study of 1.2 million singletons. BMJ 2017;357:j2563. [Ref.ID 101639]
4. Cita con resumen
Duan L, Ng A, Chen W, Spencer HT, Nguyen J, Shen AY-J, Lee M-S. ß-blocker exposure in pregnancy and risk of fetal cardiac anomalies. JAMA Intern Med 2017;177:885-7. [Ref.ID 101621]
5. Cita con resumen
Nembhard WN, Tang X, Hu Z, MacLeod S, Stowe Z, Webber D, the National Birth Defects Prevention Study. Maternal and infant genetic variants, maternal periconceptional use of selective serotonin reuptake inhibitors, and risk of congenital heart defects in offspring: population based study. BMJ 2017;356:j832. [Ref.ID 101588]
7. Cita con resumen
Bérard A, Sheehy O, Zhao J-P, Nordeng H. Use of macrolides during pregnancy and the risk of birth defects: a population-based study. Pharmacoepidemiol Drug Saf 2015;24:1241-8. [Ref.ID 99577]
8. Cita con resumen
Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA, on behalf of the National Birth Defects Prevention Study. Specific SSRIs and birth defects: bayesian analysis to interpret new data in the context of previous reports. BMJ 2015;351:h3190. [Ref.ID 99250]
9. Cita con resumen
Huybrechts KF, Palmsten K, Avorn J, Cohen LS, Holmes LB, Franklin JM, Mogun H, Levin R, Kowal M, Setoguchi S, Hernández-Díaz S. Antidepressant use in pregnancy and risk of cardiac defects. N Engl J Med 2014;370:2397-407. [Ref.ID 97770]
11.Tiene citas relacionadas Cita con resumen
Mitchell AA. Fetal risk from ACE inhibitors in the first trimester. BMJ 2011;343:857-8. [Ref.ID 91753]
12. Cita con resumen
Anónimo. FDA says chronic, high-dose fluconazole use might carry risk for birth defects . FDA U.S. Food and Drug Administration 2011:1. [Ref.ID 90912]
13. Cita con resumen
Anónimo. Fluoxétine en début de grossesse: malformations cardiaques à la naissance. Prescrire 2010;30:672. [Ref.ID 89289]
14. Cita con resumen
Anónimo. AINS, IEC, sartans, isotrétinoïne: encore trop de grossesses exposées. Prescrire 2009;29:831. [Ref.ID 87146]
15.Tiene citas relacionadas Cita con resumen
Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:3569. [Ref.ID 86766]
16.Tiene citas relacionadas Cita con resumen
Ramos E, St-André M, Rey E, Oraichi D, Bérard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations. Br J Psychiatry 2008;192:344-50. [Ref.ID 83561]
17. Cita con resumen
Anónimo. Mycophénolate: avortements spontanés et malformations congénitales. Prescrire 2008;28:435. [Ref.ID 83105]
18.
Westaby S, Archer N, Manning N, Adwani S, Grebenik C, Ormerod O, Pillai R, Wilson N. Comparison of hospital episode statistics and central cardiac audit database in public reporting of congenital heart surgery mortality. BMJ 2007;335:759-62. [Ref.ID 81277]
19. Cita con resumen
Anónimo. AINS en début de grossesse et risque de fausse couche. Prescrire 2007;27:192-3. [Ref.ID 79329]
20. Cita con resumen
Anónimo. Exposition in utero à des psychotropes: quels risques pour le nouveau-né?. Prescrire 2007;27:156. [Ref.ID 79159]
Seleccionar todas
 
 1 a 20 de 59 siguiente >>